Antoine Pau

Founded in 2017 by Truffle Capital, Holistick Medical is developing a minimally invasive medical device to close the patent foramen ovale, an abnormal communication between the right and left heart that can lead to serious strokes. Unlike currently available metallic devices, Holistick Medical offers a physiological and respectful approach to cardiac anatomy.

Skinosive is a science-driven dermo-cosmetics biotechnology company developing a technology platform in skin photoprotection. Skinosive’s technology enables long lasting skin UV protections and effective sunscreens that prevent chemicals from being absorbed into the skin and the bloodstream. This innovation aims to reduce drastically cancer and skin damages due to the sun exposure. The company is located in Paris and in Marseille. Skinosive Headquarter : 53 rue de Turbigo 75003 Paris Skinosive Lab : 60 avenue André Roussin 13016 Marseille

Based in Balma, near Toulouse (France), Vexim is a medical device company created in February 2006. The Company has specialized in the creation and marketing of minimally-invasive solutions for treating traumatic spinal pathologies. Benefitting from the financial support of it longstanding shareholder, Truffle Capital and from OSEO public subsidies, Vexim has designed and developed the SpineJack®, an implant for the reduction of mobile spinal fractures and restoration of the balance of the spinal column. The Company currently has 65 members on its staff and it has its own sales teams in France, Germany, Austria, Italy, Spain, as well as distributors in European area, in Asia area, in LATAM areas, in the Middle East, in South Africa and in the following countries where the product is currently being registered: Mexico, Bosnia and Herzegovina, Vietnam, Iran. Moreover, it was already registered in Australia. More information on www.vexim.com

Abivax is developing therapies that modulate the body’s natural immune system machinery. A clinical-stage company, Abivax leverages its immune enhancing and antiviral platforms to develop drug candidates to treat inflammatory diseases, viral diseases and liver cancer. Abivax is based on innovative research driven by the idea of modulating the body’s natural immune system mechanisms to treat diseases. With several programs in clinical trials as well as in research and preclinical development, Abivax’s pipeline is strong and diversified addressing many unmet medical needs. Abivax is currently targeting different inflammatory diseases within its clinical trial program with lead compound obefazimod: 1) Treatment Inflammatory Bowel Disease (IBD), specifically ulcerative colitis and Crohn's disease 2) Treatment of rheumatoid arthritis The second drug candidate, ABX196, is being tested in a clinical study for the treatment of liver cancer (HCC).

Affluent Medical est un nouvel acteur français de la medtech ayant pour ambition de devenir un des leaders européens dans les domaines cardiovasculaires et urologiques. Affluent Medical développe des implants innovants mini-invasifs de nouvelle génération pour restaurer des fonctions physiologiques essentielles dans ces domaines : - Kardiozis vise à prévenir les endofuites et les risques de récidive de l’anévrisme de l’aorte abdominale permettant aux patients de vivre plus sereinement face à un risque de rupture imprévisible ; - Kalios et Epygon visent à offrir des traitements chirurgicaux plus physiologiques pour la réparation ou le remplacement de la valve mitrale du cœur. Kalios permet de traiter les fuites résiduelles post-opératoire et l’insuffisance mitrale récurrente sans avoir à réopérer les patients. Epygon est aujourd’hui la seule valve transcathéter en développement permettant de restaurer les flux sanguins naturels et de sauvegarder le ventricule gauche. - Enfin, Artus est le premier sphincter artificiel activable électroniquement pour traiter l’incontinence urinaire d’effort des hommes et des femmes. Nos avancées technologies permettent d’offrir des dispositifs médicaux qui respectent davantage la physiologie du corps humain. Nos implants sont mis en place grâce à un chirurgie mini-invasive et visent à limiter les risques de récidive précoce ou tardif de la maladie. Les trois prothèses innovantes et la technologie d’Affluent Medical sont en phase sont préclinique ou clinique.

Founded in 2017 by Truffle Capital, Holistick Medical is developing a minimally invasive medical device to close the patent foramen ovale, an abnormal communication between the right and left heart that can lead to serious strokes. Unlike currently available metallic devices, Holistick Medical offers a physiological and respectful approach to cardiac anatomy.

Skinosive is a science-driven dermo-cosmetics biotechnology company developing a technology platform in skin photoprotection. Skinosive’s technology enables long lasting skin UV protections and effective sunscreens that prevent chemicals from being absorbed into the skin and the bloodstream. This innovation aims to reduce drastically cancer and skin damages due to the sun exposure. The company is located in Paris and in Marseille. Skinosive Headquarter : 53 rue de Turbigo 75003 Paris Skinosive Lab : 60 avenue André Roussin 13016 Marseille

Based in Balma, near Toulouse (France), Vexim is a medical device company created in February 2006. The Company has specialized in the creation and marketing of minimally-invasive solutions for treating traumatic spinal pathologies. Benefitting from the financial support of it longstanding shareholder, Truffle Capital and from OSEO public subsidies, Vexim has designed and developed the SpineJack®, an implant for the reduction of mobile spinal fractures and restoration of the balance of the spinal column. The Company currently has 65 members on its staff and it has its own sales teams in France, Germany, Austria, Italy, Spain, as well as distributors in European area, in Asia area, in LATAM areas, in the Middle East, in South Africa and in the following countries where the product is currently being registered: Mexico, Bosnia and Herzegovina, Vietnam, Iran. Moreover, it was already registered in Australia. More information on www.vexim.com